SUMMARY Topical acyclovir has been found in 15 out of 18 patients to control, without recurrences and in an appreciably shorter time than if steroids were used, keratoconjunctivitis induced by herpes zoster. Once steroids were started, recurrences occurred during withdrawal of steroids or after they had been stopped.
Herpes zoster ophthalmica with ocular involvement is a severe, debilitating, painful disease, leading to much ocular damage and visual loss, and frequent postherpetic neuralgia.
So far no drug treatment has been shown definitely to prevent ocular involvement or postherpetic neuralgia or to suppress ocular disease. Topical steroids have an established place in suppressing the ocular signs, but they are unsatisfactory because treatment may be prolonged and in many cases fail to prevent ocular damage. Furthermore, once topical steroid treatment has been stopped, ocular disease may recur, often with further and more severe damage such as corneal opacities with lipid deposition in them, resulting in severe visual loss.' Alternative drugs have been suggested in the treatment of this disease, but none have found universal acceptance. Topical antivirals such as idoxuridine and adenine arabinoside have no effect and can be harmful owing to their topical toxicity. Systemic adenine arabinoside has little effect, possibly because of poor drug solubility and tissue penetrance.2 There is a paucity of information on the effect of other antivirals on the ocular involvement of this disease.
For nonocular disease systemic antivirals have been tried. Cytosine arabinoside was initially thought to be effective3 but was later reported to be ineffective,4 and in a double-blind trial placebo was found to be superior. 13 has been used, but the skin toxicity of both substances must be of concern. Amantadine14 has been found in a multicentre trial to shorten postherpetic neuralgia, but there was no mention of its effect on ocular involvement. Systemic interferon significantly lessened the disease's severity in patients with malignant disease,15 but there was little information on its effect on ocular involvement. Thus there is a need for an effective drug for treating the ocular involvement of this disease.
The new antiviral acyclovir, a cyclic nucleoside, has a high specificity for virally infected cells, with little effect on uninfected cells,"' and it has been shown to be effective in treating herpes simplex ocular disease. [17] [18] [19] In tissue culture it has been found to be effective against herpes zoster virus, with inhibition of DNA synthesis,20 though it is not as effective as against the herpes simplex virus.2' In immunosuppressed patients with herpes zoster skin infection systemic acyclovir has had a favourable effect. 22 The drug has a high solubility, and after topical ocular application therapeutic aqueous levels have been found (D. Brigden, personal communication). Thus acyclovir appears to have clinical potential against herpes zoster infections, and has been used on an open basis in the topical treatment of herpes zoster ocular involvement.
Patients and methods
This study was on 21 consecutive patients who had ocular herpes zoster and in whom the skin rash had subsided within the last 28 days. Patients were 542 
Results
In 18 patients topical acyclovir alone was initially used, and it controlled the ocular disease in 15 out of them, with quick resolution of signs of the disease. In 3 patients there was an increase in the severity of the uveitis despite topical acyclovir, and topical steroids were required to suppress the signs of the uveitis (see Table 1 for details of individual patients). The average duration of treatment for those patients treated only with topical acyclovir was 12-2 weeks (Table 2) . In the 3 patients who required topical steroids, and in 3 others who were on topical steroids before acyclovir was begun, treatment was prolonged, and in all of them the ocular disease flared up as soon as the steroids were tapered off. The disease recurred once treatment had been stopped. The average duration of treatment for this group was much longer at 27 weeks (Tables 3 and 4) .
None of the patients treated with just acyclovir had a recurrence of the disease once the acyclovir had been tapered off; the average follow-up was 35 weeks. All the patients treated with steroids and acyclovir had a recurrence. In this latter group the follow-up has been shorter, as the treatment has been more prolonged ( The results can be criticised on the grounds that steroids were given in addition only to those patients with a severe ocular disease, and that acyclovir itself was given only to those patients with mild 
